Posted by Michael Wonder on 27 Oct 2020
Mavenclad (cladribine tablets) is available through public drug plans for the majority of eligible Canadians with relapsing-remitting multiple sclerosis
27 October 2020 - EMD Serono is pleased to announce that eligible patients have access to Mavenclad (cladribine tablets) through seven provincial public drug plans including the Régie de l'assurance maladie du Québec (RAMQ) and the Ontario Drug Benefit Exceptional Access Program.
This is an important step to ensure broader, equitable and timely access to Mavenclad for eligible patients across Canada.
Eligible patients in Alberta, Manitoba, New Brunswick, Nova Scotia, Ontario, Quebec and Saskatchewan living with relapsing-remitting multiple sclerosis can now access Mavenclad through their public drug programs. Mavenclad is also currently reimbursed by the Non-Insured Health Benefits Program, Veteran's Affairs Canada and most private drug insurance plans across the country.
